Bayer’s Crop Sciences division holds significant potential despite glyphosate issues. See why BAYRY stock is undervalued and ...

“As a critical industry, any disruption to the production or distribution of pharmaceutical products can have significant cost implications for the industry and health ramifications for the ...

Q4 sales of €6.7 billion exceeded expectations, with FX-neutral growth of +9.2%. Read why I remain neutral on the stock.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

E-commerce sales are expected to increase at a CAGR of 18.2% between 2021 and 2025 to reach ... and accelerated adoption during COVID-19, with diverse product categories and order value segments ...